LP
CORT icon

LMR Partners’s Corcept Therapeutics CORT Stock Holding History

LMR Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,036
Closed -$1.39M – 1537
2025
Q4 		$1.39M Buy
+40,036
New +$3.14M ﹤0.01% 904
2023
Q2 		– Sell
-343,254
Closed -$7.43M – 935
2023
Q1 		$7.43M Buy
+343,254
New +$7.53M 0.12% 200

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

LMR Partners's CORT Position: Q1 2026 in Review

LMR Partners sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 40,036 shares — an estimated $1.39M sold.

LMR Partners first reported a position in CORT in Q1 2023 and held it in 2 quarters. The position peaked at $7.43M in Q1 2023. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • LMR Partners reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • LMR Partners sold 40,036 Corcept Therapeutics shares in Q1 2026, an estimated $1.39M.
  • LMR Partners first reported a position in Corcept Therapeutics in Q1 2023 and held it in 2 quarters.
  • LMR Partners's Corcept Therapeutics position peaked at $7.43M in Q1 2023.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.